Introduction
US President Donald Trump has named India among 23 countries on Washington's list of major drug transit or illicit drug-producing nations for fiscal year 2027, even as he specifically praised Prime Minister Narendra Modi's government for its efforts against illicit opium poppy cultivation. The Presidential Determination was submitted to Congress on September 15 and made public on September 16, 2026.
What Trump Said About India
In the determination, Trump stated he welcomed Modi and the Indian government's efforts to address illicit opium poppy cultivation and bolster supply chain integrity, expressing confidence in continued cooperation through the US-India Drug Policy Framework. He clarified that India's inclusion does not reflect poorly on its bilateral law enforcement coordination.
Key Facts
- 23 countries were named in total, including China, Pakistan, Afghanistan, Mexico and Colombia.
- India was not among the four countries designated as having "failed demonstrably" to meet counter-narcotics obligations.
- Those four were Afghanistan, Bolivia, Burma (Myanmar) and Colombia.
- The list is based on geographic, commercial and economic factors enabling drug transit, regardless of a government's actual enforcement efforts.
Why Inclusion Doesn't Mean Failure
The Presidential Determination explicitly states that a country's presence on the list "is not necessarily a reflection of its government's current counterdrug efforts, or coordination with the United States." Instead, the designation is based on a combination of geographic, commercial and economic factors that allow drugs or precursor chemicals to be transited or produced, even where a government has engaged in robust enforcement.
Table: The 2027 Major's List Framework
| Category | Countries |
|---|---|
| Named on the list (23 total) | Includes India, China, Pakistan, Afghanistan, Mexico |
| Designated as "failed demonstrably" | Afghanistan, Bolivia, Burma, Colombia |
Bilateral Cooperation Context
Trump's positive framing of India comes against a backdrop of strengthening US-India cooperation on narcotics control. The two countries held the inaugural meeting of their Drug Policy Executive Working Group in Washington in January 2026, committing to joint action against narcotics trafficking, precursor chemicals and pharmaceutical supply-chain security.
The Domestic US Angle
Trump also used the determination to highlight what he described as results from tightened US border controls, saying fentanyl and other drug seizures had been cut by more than half after "four years of open border chaos," and that overdose deaths had declined sharply as a result.
Expert Insight
Foreign policy analysts note that the annual Major's List determination is a statutory reporting requirement rather than a judgment call on bilateral relations, and that Trump's explicit praise for Modi alongside India's continued listing reflects an attempt to separate the technical designation from the broader diplomatic relationship, which has been expanding across trade, defence and technology.
Key Takeaways
- India was named among 23 countries on the US major drug transit list for FY2027.
- Trump specifically praised Modi's government for tackling illicit opium cultivation.
- India was not among four countries designated as having failed counter-narcotics obligations.
- The listing reflects statutory geographic and economic criteria, not an enforcement failure judgment.
FAQ
Does India's listing mean its anti-drug efforts failed?
No. The determination explicitly states that listing does not necessarily reflect a government's counterdrug efforts or cooperation level with the US.
Which countries were rated worst on the list?
Afghanistan, Bolivia, Burma and Colombia were designated as having failed demonstrably to meet counter-narcotics obligations.
What did Trump say specifically about Modi?
He welcomed Modi's efforts to address illicit opium poppy cultivation and strengthen supply chain integrity.
Conclusion
The combination of a statutory listing alongside explicit praise underscores how the US is trying to separate procedural drug-policy designations from its broader strategic relationship with India. Continued cooperation through the bilateral working group will likely shape next year's assessment.
